Immunosuppressant related thyroid immune related adverse reactions
Conditions
Interventions
Experimental Group:Supplementing selenium yeast
Control Group:Without yeast selenium supplementatio
Sponsors
The People’s Hospital of Dazu, Chongqing
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Cancer patients who meet the diagnostic criteria for tumors; 2.Cancer patients hospitalized for ICIs treatment; 3.Capable and willing to accept informed consent;
Exclusion criteria
Exclusion criteria: 1.Non tumor patients; 2.Pregnant, preparing for pregnancy or breastfeeding women; 3.Individuals with severe organ failure and life-threatening primary diseases; 4.Individuals with mental illnesses who are unable to participate in treatment and follow-up; 5.Patients with thyroid disease (defined as baseline thyroid dysfunction or thyroid hormone therapy) and pituitary inflammation patients with central hypothyroidism;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Free triiodothyronine ,FT3;Thyroid peroxidase antibody (TPOAb);Free thyroxine,FT4;Anti-thyroglobulin antibody (TGAb);Thyroid-stimulating hormone (TSH); | — |
Countries
China
Contacts
Public ContactJian Li
The People’s Hospital of Dazu, Chongqing
Outcome results
None listed